NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part II: Chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 10, 2010, Pages 1325-1346

  Kröger, Nicolaus ^a   Bacher, Ulrike ^a   Bader, Peter ^b   Böttcher, Sebastian ^c   Borowitz, Michael J ^d   Dreger, Peter ^e   Khouri, Issa ^f   Olavarria, Eduardo ^g   Radich, Jerald ^h   Stock, Wendy ⁱ   Vose, Julie M ^j   Weisdorf, Daniel ^k   Willasch, Andre ^b   Giralt, Sergio ^f   Bishop, Michael R ^l   Wayne, Alan S ^l  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Universidad Pública de Navarra   (Spain)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Allogeneic stem cell transplantation; Chimerism; Chronic leukemias; Minimal residual disease; Myeloproliferative neoplasms, and lymphoid malignancies

Indexed keywords

BCR ABL PROTEIN; BLINATUMOMAB; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN HEAVY CHAIN; JANUS KINASE 2; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CHIMERA; CHROMOSOME ANALYSIS; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DONOR LYMPHOCYTE INFUSION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MULTIPARAMETER FLOW CYTOMETRY; MULTIPLE MYELOMA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POLYCYTHEMIA VERA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOGRAPHY; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; THROMBOCYTHEMIA; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; MYELOPROLIFERATIVE DISORDERS; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956309607     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.001     Document Type: Article

References (157)

1. Kröger N., Bacher U., Bader P., et al. Disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation-Part I: methods, acute leukemias and MDS. Biol Blood Marrow Transplant 2010, 16:1187-1211.
2. Raanani P., Dazzi F., Sohal J., et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997, 99:945-950.
3. Bader P., Klingebiel T., Schaudt A., et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999, 13:2079-2086.
4. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009, 27:6041-6051.
5. Goldman J.M. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007, 110:2828-2837.
6. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
7. Radich J.P., Olavarria E., Apperley J.F. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 2004, 18:685-702.
8. Dazzi F., Szydlo R.M., Craddock C., et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000, 95:67-71.
9. Radich J.P., Gehly G., Gooley T., et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638.
10. Olavarria E., Kanfer E., Szydlo R., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcription-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
11. Kaeda J., O'Shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107:4171-4176.
12. Tariq I.M., Agnes Y., Richard M.S., et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001, 115:569-574.
13. Cross N.C., Hughes T.P., Feng L., et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993, 84:67-74.
14. Lion T., Henn T., Gaiger A. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993, 341:275-279.
15. Hughes T.P., Morgan G.J., Martiat P., et al. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991, 77:874-878.
16. Roth M.S., Antin J.H., Ash R., et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992, 79:276-282.
17. Lin F., van Rhee F., Goldman J.M. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478.
18. Drobyski W.R., Endean D.J., Klein Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myeloid leukemia. Br J Haematol 1997, 98:458-466.
19. Hochhaus A., Lin F., Reiter A., et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996, 87:1549-1555.
20. Cross N.C., Feng L., Chase A. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993, 82:1929-1936.
21. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
22. Muller M.C., Saglio G., Lin F., et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007, 92:970-973.
23. Cross N.C.P., Hughes T.P., Hochhaus A., Goldman J.M. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2008, 32:505-506.
24. Radich J.P., Gooley T., Bryant E., et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients " late," 18 months or more after transplantation. Blood 2001, 98:1701-1707.
25. Yong A.S., JM.G Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:827-828.
26. Goldman J.M., Sobocinski K.A., Zhang M.-J., et al. Long-term outcome after allogeneic hematopoietic transplantation (HCT) for CML. Biol Blood Marrow Transplant 2006, 12(Suppl 1):17. (Abstract no. 40).
27. Dazzi F. Monitoring of minimal residual disease after allografting: a requirement to guide DLI treatment?. Ann Hematol 2002, 81(Suppl 2:):S29-S30.
28. Serrano J., Roman J., Sanchez J., et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection precede cytogenetic relapse. Blood 2000, 95:2659-2665.
29. Rapanotti M.C., Arcese W., Buffolino S., et al. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. Bone Marrow Transplant 1997, 19:703-707.
30. Roman J., Serrano J., Jimenez A., et al. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia. Haematologica 2000, 85:173-180.
31. Hess G., Bunjes D., Siegert W., et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005, 23:7583-7593.
32. Chiorean E.G., DeFor T.E., Weisdorf D.J., et al. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:171-177.
33. Levenga H., Woestenenk R., Schattenberg A.V., et al. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplant 2007, 40:585-592.
34. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
35. Tefferi A., Barosi G., Mesa R.A., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1497-1503.
36. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007, 22:14-22.
37. Orazi A., Germing U. The myelodysplastic//myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008, 22:1308-1319.
38. Gratwohl A., Baldomero H., Schwendener A., et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009, 43:275-291.
39. Kröger N., Thiele J., Zander A., et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007, 35:1719-1722.
40. Siebolts J.T., Zander T., Ditschkowski M., et al. Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF. Oncol Rep 2008, 19:287-292.
41. Kröger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321.
42. Alchalby H., Badbaran A., Zabelina T., et al. Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010, May 20 [Epub ahead of print].
43. Steckel N.K., Koldehoff M., Ditschkowski M., et al. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007, 83:1518-1520.
44. Alchalby H., Badbaran A., Bacher U., et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 2010, Jan 11 [Epub ahead of print].
45. Tefferi A., Lasho T.L., Gilliland G., et al. JAK2 Mutations in Myeloproliferative Disorders. N Engl J Med 2005, 353:1416-1417.
46. Bacher U., Haferlach T., Schnittger S., et al. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008, 42:145-157.
47. Fiorini A., Reddiconto G., Farina G., et al. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. Leukemia 2006, 20:2198-2199.
48. Guillermo J.R.-A., Javier G.-E., Virginia R.-N., et al. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. Am J Hematol 2007, 82:400-402.
49. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002, 99:2255-2258.
50. Kröger N., Klyuchnikov E., Badbaran A., et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009, 113:1866-1868.
51. Lippert E.G.F., Hammond E., Jelinek J., et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009, 94:38-45.
52. Hermouet S., Dobo I., Lippert E., et al. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2V617F. Leukemia 2007, 21:1128-1130.
53. Koren-Michowitz M., Shimoni A., Vivante A., et al. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008, 32:421-427.
54. Bacher U., Badbaran A., Zander A.R., et al. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med 2009 July 23, [Epub ahead of print].
55. Thiele J., VE, Siebolts U., Kvasnicka H.M., et al. Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation. Histol Histopathol 2007, 22:365-372.
56. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood 2008, 111:5446-5456.
57. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
58. Böttcher S., Ritgen M., Pott C., et al. Comparative analysis of minimal residual disease detection using four color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18:1637-1645.
59. Schultze J.L., Donovan J.W., Gribben J.G. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 1999, 77:259-265.
60. Farina L., Carniti C., Dodero A., et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009, 94:654-662.
61. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
62. Provan D., Bartlett-Pandite L., Zwicky C., et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88:2228-2235.
63. Voena C., Ladetto M., Astolfi M., et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997, 11:1793-1798.
64. van der Velden V.H., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611.
65. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004, 104:2600-2602.
66. Rawstron A.C., Villamor N., Ritgen M., et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21:956-964.
67. Böttcher S., Stilgenbauer S., Busch R., et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy-a comparative analysis. Leukemia 2009, 23:2007-2017.
68. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
69. Champlin R., Khouri I., Kornblau S., et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999, 11:87-95.
70. Ben Bassat I., Raanani P., Gale R.P. Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 2007, 39:441-446.
71. Gribben J.G. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2009, 15(Suppl 1):53-58.
72. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2009, 2009:596-603.
73. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
74. Kollgaard T., Petersen S.L., Hadrup S.R., et al. Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia 2005, 19:2273-2280.
75. Donovan J.W., Andersen N.S., Poor C.M., et al. Prospective analysis of minimal residual disease detection in patients with CLL undergoing autologous and allogeneic BMT. Blood 1998, 92(Suppl 1):652a.
76. Ritgen M., Böttcher S., Stilgenbauer S., et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008, 22:1377-1386.
77. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008, 26:4912-4920.
78. Khouri I.F., Saliba R.M., Admirand J., et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007, 137:355-363.
79. Moreno C., Villamor N., Esteve J., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563-4569.
80. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic Transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities. Clin Cancer Res 2005, 11:7757-7763.
81. Drobyski W.R., Hessner M., Klein J.P., et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999, 94:434-441.
82. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood 2006, 107:1724-1730.
83. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003, 21:2747-2753.
84. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3819-3829.
85. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
86. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006, 12:1056-1064.
87. Coiffier B., Lepretre S., Pedersen L.M., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008, 111:1094-1100.
88. Bargou R., Leo E., Zugmaier G., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
89. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
90. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
91. Gribben J.G., Neuberg D., Freedman A.S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993, 81:3449-3457.
92. Summers K.E., Golf L.K., Wilson A.G., et al. Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma. J Clin Oncol 2001, 19:420-424.
93. Bladé J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
94. Lahuerta J.J., Martinez-Lopez J., Serna J.D., et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000, 109:438-446.
95. Martinez-Lopez J., Blade J., de la Rubia J., et al. Prognostic impact of posttransplantation complete remission in multiple myeloma. Final results of a prospective study in a series of homogenously treated patients. Haematologica 2007, 92:42.
96. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996, 88:2787-2793.
97. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centers. Br J Haematol 2001, 113:209-216.
98. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
99. Kröger N., Einsele H., Wolff D., et al. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant 2003, 31:973-979.
100. Kröger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002, 100:755-760.
101. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003, 102:3447-3454.
102. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
103. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
104. Terpos E., Dimopoulos M.A. Myeloma bone disease:pathophysiology and management. Ann Oncol 2005, 16:1223-1231.
105. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108:3992-3996.
106. Wahlin A., Holm J., Ostermann G., et al. Evaluation of serial bone X-ray examination in multiple myeloma. Acta Med Scand 1982, 212:385-387.
107. Dimopoulos M., Terpos E., Comenzo R.L., et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009, 23(9):1545-1556.
108. Collins C.D. Problems monitoring response in multiple myeloma. Cancer Imaging 2005, 5(Spec No A):S119-S126.
109. Scutellari P.N., Addonisio G., Righi R., et al. Diagnostic imaging of bone metastases. Radiol Med 2000, 100:429-435.
110. Horger M., Kanz L., Denecke B., et al. The benefit of using whole-body, low-dose, non-enhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007, 109:1617-1626.
111. Hur J., Yoo C.S., Ryu Y.H., et al. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-position emission tomography. J Comput Assist Tomogr 2007, 31:342-347.
112. Chassang M., Grimaud A., Cucchi J.M., et al. Can low-dose computed tomography scan replace conventional radiography? An evaluation based on imaging myelomas, bone metastases and fractures from osteoporosis. Clin Imaging 2007, 31:225-227.
113. Baur-Melnyk A., Buhmann S., Durr I.R., et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005, 55:56-63.
114. Jaffe J., Williams M.P., Cherryman G.R., et al. Magnetic resonance imaging in myeloma. Lancet 1988, 1:1162-1163.
115. Moulopoulos L.A., Dimopoulos M.A. Magnetic resonance imaging of bone marrow in hematologic malignancies. Blood 1997, 90:2127-2147.
116. Libshitz H.I., Malthouse S.R., Cunningham D., et al. Multiple myeloma: appearnace at MR imaging. Radiology 1992, 182:833-837.
117. Moulopoulos L.A., Varma D.G., Dimoupoulos M.A., et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992, 185:833-840.
118. Lecouvet F.E., Makghem J., Michaux L., et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999, 106:35-39.
119. Walker R., Barlogie B., Haessler J., et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007, 25:1121-1128.
120. Moulopoulos L.A., Dimopoulos M.A., Weber D., et al. Magnetic resonance imaging in the staging of solitary plasmocytoma of bone. J Clin Oncol 1993, 11:1311-1315.
121. Sculellari P.N., Spanedda R., Feggi L.M., et al. The value and imitations of total body scan in diagnosis of multiple myeloma: a comparison with conventional skeletal radiography. Haematologica 1985, 70:136-142.
122. Woolfenden J.M., Pitt M.J., Durie B.G., et al. Comparison of bone scintigrafphy in multiple myeloma. Radiology 1980, 134:723-728.
123. 99m-Tc-MIBI scintigraphy in multiple myeloma. Br J Cancer 1996, 74:1815-1820.
124. 99 m Tc-MIBI in patients with multiple myeloma. Lur J Med 2001, 28:1430-1432.
125. Alper E., Gurel M., Evrensel T., et al. 99mTc-MIBI scintigraphy in unrelated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy. Nucl Med Commun 2003, 24:537-542.
126. Mirzaei S., Filipits M., Keck A., et al. Comparison of Technelium-99m-MIBI Imaging with MRI for detection of spine involvement in patients with multiple myeloma. BMC Nucl Med 2003, 3:2.
127. Bredella M.A., Steinbach L., Caputo G., et al. Value of FDG PET in th eassessment of patients with multiple myeloma. AJR Am J Roentgenol 2005, 184:1199-1204.
128. Nosas-Garcia S., Moehler I., Wasser K., et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 2005, 22:154-162.
129. Durie B.G.M., Waxman A.D., D'Aginola A., et al. Whole-body F-FDG PET identifies high-risk myeloma. J Nucl Med 2002, 43:1457-1463.
130. Schirmeister H., Buck A.K., Bergmann L., et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm 2003, 18:841-845.
131. Nanni C., Rubello D., Zamagni E., et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmacytoma of bone. In Viva 2008, 22:513-517.
132. Zamagni E., Nanni C., Patriarca F., et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007, 92:50-55.
133. Fonti R., Salvatore B., Quarantelli M., et al. 18F-FDG PET/CT, 99mTc-MIBI and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008, 49:195-200.
134. Hur J., Yoon C.S., Ryu Y.H., et al. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma. Acta Radiol 2008, 49:427-435.
135. Bader P., Beck J., Frey A., et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patient with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998, 21:487-495.
136. Luft T., Moos M., Goldschmidt H., et al. Dissociation of putative graft-versus-haematopoiesis and graft-versus myeloma effect in patients with rapidly progressive multiple myeloma. Br J Haematol 2005, 23:646-653.
137. Kröger N., Zagrivnaja M., Schwartz S., et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly-sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006 May, 34:688-694.
138. Arzoumanian V., Hoering A., Sawyer J., et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008, 22:850-855.
139. Sawyer J.R., Waldron J.A., Jagannath S., et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995, 82:41-49.
140. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109:3489-3495.
141. Schilling G., Hansen T., Shimoni A., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008, 22:1250-1255.
142. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32, t(4;14)(p16.3;q32) and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
143. Kröger N., Schilling G., Einsele H., et al. Depletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004, 103:4056-4061.
144. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
145. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after
146. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
147. Kröger N., Badbaran A., Lioznov M., et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009, 37:791-798.
148. Rawstron A.C., Orfao A., Beksac M., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438.
149. Lioznov M., Badbaran A., Fehse B., et al. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. Bone Marrow Transplant 2008, 41:913-916.
150. Sarasquete M.E., García-Sanz R., Gonzáles D., et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005, 90:1365-1372.
151. Martínez-Sánchez P., Montejano L., Sarasquete M.E., et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achievibg molecular response. Br J Haematol 2008, 142:766-774.
152. Paiva B., Vidriales M.B., Cerveró J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
153. Bradwell A.R., Carr-Smith H.D., Mead G.P., et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003, 361:489-491.
154. Dispenzieri A., Kyle R., Merlini G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224.
155. Kröger N., Asenova S., Gerritzen A., et al. Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. Blood 2010, 115:3413-3414.
156. Mösbauer U., Ayuk F., Schieder H., et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007, 92:275-276.
157. Atanackovic D., Luetkens T., Hildebrandt Y., et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009, 15:1343-1352.